

# **Investor Presentation**

17 May 2023 (ASX: AUA)

Approved for release by the Board of Audeara Limited.

# **Disclaimer** | Important information

#### 17 May 2023

This presentation has been prepared by Audeara Limited ACN 604 368 443 (Company) for the sole purpose of providing the Recipient with general information only.

This presentation does not purport to be complete, nor does it contain all the information that a prospective investor may require in connection with an investment in the Company. Specifically, this presentation does not purport to contain all of the information a recipient of this presentation requires to make an informed assessment of the Company's assets and liabilities, financial position and performance, profits, losses and prospects.


This presentation is not a prospectus, product disclosure statement, pathfinder document or any other disclosure document or other offering document or contract under Australian law or any other law.

This presentation does not constitute an invitation or offer by the Company for the purchase or subscription of Shares or other securities and nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy securities in the Company.

Furthermore, this document does not advertise any such invitation or offer and does not constitute financial product advice or advice relating to investment matters.



# **Business overview**





# Market updates | 17 May 2023

- Quarterly revenue up 104% vs Q3 FY22
- Q3 FY23 cash receipts \$1.01m, up 168% from the pcp
- YTD FY23 cash receipts \$2.46m, up 85% from the pcp
- YTD FY23 net cash outflows \$2.28m reduced 23% from the pcp
- \$3.25 million in cash or equivalents at 31st March

Audeara	AUA Technology
<ul> <li>WS Audiology Bloom Hoerakustik product launch</li> <li>WS Audiology HearUSA product launch</li> <li>Amplifon product launch preparation being finalised to 11 country pipeline</li> </ul>	<ul> <li>Clinico cooperative agreement executed following on from strategic investment in Q2 FY23</li> <li>AUA Technology engagement by a leading musical instrument company on track to meet development timelines for product manufacture H1 FY24</li> </ul>
• Demant Group USA: first sales into Hearing Life	



# Audeara

Sn

Hardware and software solutions for the hearing industry



# The Audeara difference

Audeara headphones use a health-check algorithm<sup>^</sup> to tailor sound to a unique hearing profile.

Sound is clearer, not louder by only amplifying frequencies the user can't hear as well.

The listener experiences clearer sound while connecting to the moments that bring them joy – whether that's watching a favourite TV show, listening to music or FaceTiming with family.

# Who is Audeara for?

People with a hearing loss, who aren't ready for hearing aids



Need

Wants to hear the TV better and/or alleviate household tension due to loud volume Current hearing aid or cochlear implant wearers



Need

Seeking a complementary device for entertainment

Not for the purpose of medical diagnosis.



# **Clients** | Audiology clinics

#### The problem for audiology clinics

#### 45%

of self declared hearing impaired adopt hearing aids\*

#### 35%

of hearing impaired people who visit a clinic **leave empty handed**<sup>\*</sup>

#### **10 Years**

Average time hearing aid users wait before getting help for hearing loss<sup>^</sup>

#### The value of Audeara to audiology clinics

### 

#### Additional revenue stream

As an Assistive Listening Device (ALD), Audeara provides clinics with an additional revenue stream.

#### **Increase customer conversion**

Clinics who recommend Audeara increase customer conversion rates and reduce the time to client's first purchase for customers who aren't ready to commit to hearing aids.

#### Increase lifetime value



~


Audeara increases the lifetime value of their clients, by providing a solution **on the way to** or **as well as** a hearing aid. We **never** position ourselves **instead of** a hearing aid.



EARS

# **Clients** | Audiology clinics

Amplifon - GLOBAL OPERATIONS - November 2022



4 Specsavers Annual Review 2022

AUDEARA

# **International distribution**

## expansion of clinics stocking Audeara

#### Currently stocked in 6 countries

- AustraliaUSA
- a ► Hungary ► Austria
  - ł
- ► Taiwan
- New Zealand

#### FY24 Pipeline 11 countries

- ItalyFrance
- Germany
- Spain
- Netherlands
   Portugal

► UK

Switzerland

Belgium

Poland

Singapore

#### ASIAPAC Australia

- Currently stocked in over 1400 clinics.
- Primary revenue stream FY23 Taiwan
- Currently stocked in Clinico Inc. clinics
   the largest audiology chain in Taiwan.
- Cooperative agreement signed with Clinico to develop healthy hearing earbuds.

#### AMERICAS

#### USA

- Hearing Life (Demant Group)
- HearUSA (WSA)

#### EMEA

- Significant growth prospects ahead with a coordinated rollout to be executed to ensure market success.
- Underpinned by Amplifon Territories
- First Country launched with WSA
- Demant negotiations underway





# **AUA Technology**

Innovative listening solutions



# **AUA Technology**

Third party product development and technology licensing

Leverage Audeara Proprietary Technology for strategic opportunities outside of audiology industry.

#### Audeara product pipeline

Utilise Audeara Proprietary Technology to develop products in Audeara's product pipeline.

#### Research and development capabilities

Research and development driving Audeara Proprietary Technology including hardware, firmware and software. IP Portfolio - Patents/ Trademarks

# **Global musical instrument brand**

Product development agreement

#### Engineering fee for services

- Design
- Sourcing
- Product development
- Post market support

Contract manufacturing and licensing

High volume consumer markets with global reach.

Highly scalable products with well established sales channels.







# **Clinico Inc.**

Cooperative agreement following strategic \$2.8M investment

Clear path to market

#### Product development

Developing a series of healthy hearing earbuds in conjunction with Clinico.

Expected completion within the next 18 months.

#### Exclusive distribution

In Taiwan and China, Audeara will be exclusively distributed through Clinico.

Audeara branded products will be placed as a priority to sell.




Clinico Inc. is a Taiwanese company, based in Taipei, and the largest hearing aid retailer in Taiwan with over 33% market share, and a presence in Taiwan and China.





# Audeara product pipeline



#### Tailored listening software

- Audeara app (consumer mobile app)
- AudAssist (desktop app for clinics)

#### Research and development underway

- Musicians
  - Hearing protection that doesn't sacrifice sound quality.
- ► Kids
  - Volume limiting headphones that don't sacrifice sound quality.
- ▶ Gaming
  - Dr Ian O'Brien, Audeara research engineer, attending WHO Safe Listening Devices council in Geneva.





# Revenue


NS

Continual year on year growth + additional revenue streams



# Sales by Half Year

Outlook



#### AUA Technology

Engineering Services

#### International Wholesale

- US Independents, global chains
- EU global chains
- Taiwan Clinico

#### Australian Wholesale

Focus on increasing sales per clinic

#### Australian Retail

► NDIS + E-Commerce





# Milestones and targets 2023 - 2024

#### Previous quarter January - March

#### Audeara

- Australia: Wholesale and Retail Sales continued Year-on-Year Growth
  - ▶ Wholesale up 78% on the pcp.
  - ▶ Retail sales up 51% on the pcp.
- Europe: Preparations for launch into 11 countries in Europe with global chains.
- USA: First Sales into Demant and WS Audiology corporate owned clinics.

#### **AUA Technology**

- Achieved product development milestones for music industry partner.
- Strategic Product Partnership with Clinico Inc. in Taiwan and China following on from strategic investment.

✓ WS Audiology Austria

Current quarter

April - June

- rollout to 21 clinics
- **WS Audiology USA** 
  - pilot in flagship location with goal to expand through to 360 locations
- First POs for country launches under global Amplifon agreement

#### FY24 targets

#### Audeara

- US Global Clinic Groups
  - Expansion beyond trial sites to national rollout
- ► EU Global Clinic Groups
  - ▶ 11 European countries

#### AUA Technology

- First PO from global music industry brand
- Healthy hearing earbuds introduction to Taiwanese audiology market

# Contact

INVESTOR ENQUIRIES

**Dr James Fielding** Managing Director and Chief Executive Officer

james.fielding@audeara.com



# **Company snapshot**

	Enterprise value (A\$)		
	Market cap	Share price \$0.046 at 16 May 2023	\$6.59M
-	Cash	As at 31 March 2023	\$3.247M
	Debt	As at 31 March 2023	\$0
	Enterprise value	16 May 2023	\$3.343M

Key operating metrics						
Rev. FY22	30 June 2022	\$2.07M	+85% on FY21			
Rev. YTD FY23	31 March 2023	\$2.03M	+56% on pcp			
Cash outflow YTD FY23	31 March 2023	(\$2.28M)	-ve 24% on pcp			

Shares	Percentage
28,000,000	19.5%
43,515,087	30.0%
31,302,323	22.2%
2	13,515,087







## **Board Members**



Dr. James Fielding CEO and Managing Director

Dr Fielding completed dual bachelor's degrees in business management and Biomedical Science at University of Queensland (UQ).

After working in finance and public relations in New York, Dr Fielding commenced a Bachelor of Medicine/Bachelor Surgery, earning a scholarship for UQ's Medical Leadership Program.

James left full time clinical medicine to focus on Audeara.

Dr Fielding was appointed to the Audeara Board 23 February 2015.



David Trimboli Non-Executive Chairman

Mr Trimboli helped launch Audeara in 2015. He has 10 years experience with the international commodity trading and asset management company, Glencore International AG, as a senior coal trader.

David has since established two Switzerland and Australia based investments, the latter being Seefeld Investments Pty Ltd.

Mr Trimboli was appointed to the Board 27 August 2015.



Pasquale 'Paddy' Rombola Non-Executive Director

Mr Rombola's experience is in the investment banking industry in Australia, United Kingdom and Asia, specialising in Asian and Australian equities at both Morgan Stanley and Deutsche Bank.

One of his roles at Morgan Stanley was Head of the ASEAN Equity and Global Head of the Asia Equity Sales. Paddy is currently Chairman of Advantage Agriculture Pty Ltd and Microba Life Sciences Limited.

Mr Rombola was appointed to the Board 31 March 2021.



Dr. Elaine Saunders Non-Executive Director

Dr Saunders is a Biomedical Engineer, Audiological Scientist, business-woman, author, speaker and professional director.

She co-founded and led two award-winning companies which changed the hearing industry: Blamey Saunders hears, and Dynamic Hearing Pty Ltd. Elaine now leads Bingarra Scale-Up Solutions, specialising in helping businesses through growth.

Dr Saunders was appointed to the Audeara Board 1 January 2022.



Bill Peng Executive Director

Mr Peng has extensive experience in the electronics industry, including the production of electronic materials, components, and semi-product through to finished products.

Bill brings extensive business experience across operational, supply chain management, product development and international sales, particularly in the Asia Pacific Region.

Mr Peng was appointed to the Audeara Board 5 August 2022.

AUDEARA